Prosecution Insights
Last updated: April 19, 2026

Foundation Medicine Inc.

11 pending office actions

Portfolio Summary

11
Total Pending OAs
1
Final Rejections
10
Non-Final OAs

Pending Office Actions

App #TitleExaminerArt UnitStatusFiled
19171081 SYSTEMS AND METHODS FOR EVALUATING TUMOR FRACTION VANNI, GEORGE STEVEN 1686 Non-Final OA Apr 04, 2025
18975942 METHODS AND SYSTEMS FOR CHARACTERIZING AND TREATING A DISEASE GARTLAND, SCOTT D 3685 Non-Final OA Dec 10, 2024
18570006 METHODS OF USING SOMATIC HLA-I LOH TO PREDICT RESPONSE OF IMMUNE CHECKPOINT INHIBITOR-TREATED PATIENTS WITH LUNG CANCER GRAY, JESSICA 1682 Non-Final OA Dec 13, 2023
18027826 METHODS FOR DETERMINING VARIANT FREQUENCY AND MONITORING DISEASE PROGRESSION NEWTON, CHAD A 3681 Non-Final OA Mar 22, 2023
18025365 METHODS OF DETECTING AN INACTIVATING MUTATION OF PBRM1 IN MENINGIOMA SITTON, JEHANNE SOUAYA 1682 Non-Final OA Mar 08, 2023
18008410 METHODS AND SYSTEMS FOR DISTINGUISHING SOMATIC GENOMIC SEQUENCES FROM GERMLINE GENOMIC SEQUENCES PLAYER, ROBERT AUSTIN 1686 Non-Final OA Dec 05, 2022
17746712 PRECISION ENRICHMENT OF PATHOLOGY SPECIMENS SANFORD, DIANA PATRICIA 1687 Non-Final OA May 17, 2022
17772451 SYSTEMS AND METHODS FOR NUCLEIC ACID SEQUENCING ASSEMBLY ASSOCIATED WITH IN SILICO GENOMIC VARIANT IDENTIFICATION SABOUR, GHAZAL 1686 Non-Final OA Apr 27, 2022
17535492 METHODS OF TREATING UROTHELIAL CARCINOMA GODDARD, LAURA B 1642 Non-Final OA Nov 24, 2021
17162718 PREDICTION AND CHARACTERIZATION OF DLBCL CELL OF ORIGIN SUBTYPES HANEY, AMANDA MARIE 1682 Final Rejection Jan 29, 2021
16579500 SYSTEM AND METHOD FOR MANAGING GENOMIC INFORMATION WOITACH, JOSEPH T 1687 Non-Final OA Sep 23, 2019

Managing Foundation Medicine Inc.'s Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month